A confidential Justice Department report found Purdue Pharma was aware early on that OxyContin was being crushed and snorted for its powerful narcotic, but continued to promote it as less addictive. NYT reports. » Read More
By: Bertha Coombs
Analysts say the dual announcements mean Quest and LabCorp likely did not have to resort to rock-bottom pricing to hold onto their agreements. » Read More |
An ingestible micro-bio-electronic device has been developed at MIT that can detect blood in the stomach. It could end the need for endoscopy procedures. » Read More |
AstraZeneca's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients. » Read More |
Overshadowed by the opioid crisis, synthetic marijuana is a serious — and sometimes deadly — problem in America, according to US News & World Report.
Mylan is becoming increasingly frustrated with Pfizer's inability to tackle the shortage of the life-saving EpiPen, which has been placed on the FDA's official shortage list, the Financial Times reports.
A new study is sounding the alarm about misuse of medication for attention deficit hyperactivity disorder, according to US News & World Report.
Aaron Traywick envisioned a future in which self-taught scientists would cure diseases and bend the human body to their will, NYT reports.
Biotech companies and pharmacy benefit managers are outperforming the market, despite new pressure on drugmakers.
Roche's new hemophilia drug Hemlibra dramatically reduced bleeding in a broad population of hemophilia patients, results from two clinical trials showed.
Aimovig from Amgen and Novartis could become a $1 billion to $2 billion business in five years, say one Wall Street analyst.
Major pharmaceutical companies have spent billions of dollars in an effort to patent their products and avoid generic copies of blockbuster medicines, but the FDA commissioner has vowed to end this, the New York Times reports.
FTC approval gives Tepper's Appaloosa Management flexibility if it decides it wants to be more than a passive investor.
Amgen won U.S. Food and Drug Administration approval on Thursday for the first drug to prevent migraine headaches in adults. The drug, Aimovig, which is given monthly by self-injection, will have a list price of $6,900 a year, or $575 a month.
The error led to an overestimation of the amount of prescription fentanyl being used in the U.S.
"There are going to be changes in the pricing system" for prescription drugs, Johnson & Johnson chief Alex Gorsky acknowledges.
J&J is still the global leader in the category, but says it needs to make a change to stem a sales decline.
General Counsel Felix Ehrat will leave Novartis over his role in a $1.2 million contract it struck with the personal lawyer for President Donald Trump.
Drug pricing strategies overseas are adversely leading to higher prescription costs in the U.S. and around the world, he says.
Democratic Republic of Congo has reported 39 cases of Ebola, including 19 deaths, according to the World Health Organization.
Get the best of CNBC in your inbox
Data also provided by 
